LANOXIN

This brand name is authorized in United States. It is also authorized in Australia, Cyprus, Hong Kong SAR China, Ireland, Israel, Lithuania, Malta, Mexico, Netherlands, New Zealand, Singapore, South Africa, UK.

Active ingredients

The drug LANOXIN contains one active pharmaceutical ingredient (API):

1	Digoxin UNII 73K4184T59 - DIGOXIN
	Digoxin increases contractility of the myocardium by direct activity. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+ - K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect.
	Read more about Digoxin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LANOXIN Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
LANOXIN Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
Lanoxin 125 Tablets	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01AA05	Digoxin	C Cardiovascular system → C01 Cardiac therapy → C01A Cardiac glycosides → C01AA Digitalis glycosides
Discover more medicines within C01AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1322N, 2605D, 3164M
GB	Medicines & Healthcare Products Regulatory Agency	104259, 13615, 13641, 13665, 14280, 161967, 175676, 185886, 27766
HK	Department of Health Drug Office	03780, 03795, 03798, 60869
IE	Health Products Regulatory Authority	30570, 30597, 30627, 63649
IL	מִשְׂרַד הַבְּרִיאוּת	1110
LT	Valstybinė vaistų kontrolės tarnyba	1089040, 1090989
MT	Medicines Authority	AA1343/00601, AA565/02904, MA955/00701, MA955/00702, PI1438/03201A, PI1438/03202A
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	28448
NL	Z-Index G-Standaard	12129232, 12400378
NL	Z-Index G-Standaard, PRK	15954, 1635, 5916, 5924, 5932
NZ	Medicines and Medical Devices Safety Authority	660, 661, 662
SG	Health Sciences Authority	00544P, 00547P, 01198P, 01203P
US	FDA, National Drug Code	59212-240, 59212-242, 59212-249, 70515-260, 70515-261, 70515-262, 70515-263, 71610-019
ZA	Health Products Regulatory Authority	J/6.3/302